novo nordisk glp-1 weight loss Nordisk's weight-loss pill wins FDA approval Novo Nordisk Finds Medicare Patients

Semaglutide has demonstrated a wide range of benefits within the GLP-1 class beyond glycemic control and weight loss, particularly for people with cardiometabolic disease

Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the activity of vagal pre-ganglionic neurones

Most patients regain a portion of the weight if they stop without a structured maintenance plan

Current evidence supports substantial preclinical promise, but clinical translation remains limited by inconsistent formulations, uncertain dosing, and the need for larger human trials

The effects remain an area of active research [2][19][20]

(10) Studies suggest that carnitine levels may decrease with age, potentially contributing to reduced cellular energy production